Opendata, web and dolomites

VANGUARD SIGNED

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VANGUARD project word cloud

Explore the words cloud of the VANGUARD project. It provides you a very rough idea of what is the project "VANGUARD" about.

individuals    edited    scientists    organoids    pancreas    disease    majority    devastating    bioartificial    producing    cd47    langerhans    genome    membrane    atmp    complications    anti    ngo    hydrogel    components    larger    chronic    vitro    clinical    accessibility    mice    forty    haecs    epithelial    locally    worldwide    potency    managed    replacement    vanguard    inflammatory    graft    urgent    diabetes    human    limited    medicinal    academic    implantability    extracellular    translational    reconstituted    infinite    destruction    immunomodulatory    diabetic    cell    overexpress    mechanical    immune    construct    therapies    insulin    model    vast    molecules    l1    utilizing    smes    completion    xenogeneic    beta    islet    expertise    delivered    amniotic    therapeutic    matrix    social    implantation    sources    blood    vivo    endothelial    revascularization    haec    assembling    rapid    outgrowth    pd    hla    confer    consists    transplantation    constructs    ethical    boecs    safety    patients    therapy    biocompatibility    stem    million    protection    suffer    cells    release   

Project "VANGUARD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE GENEVE 

Organization address
address: RUE DU GENERAL DUFOUR 24
city: GENEVE
postcode: 1211
website: www.unige.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 6˙844˙625 €
 EC max contribution 6˙844˙625 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE GENEVE CH (GENEVE) coordinator 1˙995˙946.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 1˙049˙500.00
3    UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO IT (VERCELLI) participant 936˙875.00
4    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 804˙375.00
5    KUGELMEIERS AG CH (ERLENBACH) participant 701˙250.00
6    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 523˙812.00
7    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 393˙116.00
8    ACCELOPMENT AG CH (ZUERICH) participant 384˙750.00
9    EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION NL (AMSTERDAM) participant 55˙000.00

Map

 Project objective

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients. The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin- producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model. The consortium consists of 5 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation. The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing “infinite” sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VANGUARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VANGUARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More